420 with CNW — Biden Signs Infrastructure Measure to Allow Studies on Cannabis from State-Legal Dispensaries

November 24, 2021 04:20:29

Earlier this week, President Joseph Biden signed a large-scale infrastructure outlining provisions that will permit scientists to conduct research on the cannabis that consumers buy from state-legal dispensaries. This bill encourages states that have enacted laws to legalize the herb to educate individuals on impaired driving.

The bill also stipulates that the secretary of Health and Human Services and the attorney general will need to collaborate with the secretary of transportation to compile a public report within two years of the measure’s enactment that will include recommendations on permitting researchers to access retail-level cannabis to study impaired driving.

The marijuana provision also states that the report must contain recommendations on the establishment of a clearinghouse, which will gather and distribute strains and samples of cannabis for scientific research. This is in addition to stating that the research report must extensively assess federal regulatory and statutory barriers to research on cannabis-impaired driving.

The cannabis provision also requires that researchers from states that have yet to legalize the plant be allowed access to cannabis products being sold in states that have ended cannabis prohibition. This development comes as Democratic legislators in Congress strive to advance several other marijuana legalization measures, including a federal initiative that was approved by the House Judiciary Committee in September.

In the same month, the House passed a defense spending measure that includes protections for financial institutions that work with state-legal marijuana businesses.

Separately, the House Veterans’ Affairs Committee approved a measure this month that directs the Veterans Affairs Department to carry out clinical trials on the medical benefits of cannabis for military veterans with chronic pain and post-traumatic stress disorder.

Meanwhile, the DEA has also addressed some of the issues researchers face when it comes to studying cannabis. The agency recently announced that it would be approving new applications for federally authorized marijuana manufacturers, requested for research purposes. For about five decades now, the University of Mississippi was the only facility federally authorized to manufacture marijuana for research.

Additionally, the Drug Enforcement Administration revealed that it would be increasing the production of cannabis and psychedelic substances, such as psilocybin, MDMA and LSD, for research purposes. Its objective is to facilitate the development of novel federally approved medications.

The amount of cannabis to be produced will increase to 2 million grams while the amount of psilocybin to be produced will be 1,500 grams, which is quite an increase from the initial 50 grams.

When the studies on dispensary-sourced marijuana envisaged in this law commence, they would greatly benefit from the AI tools designed by companies such as RYAH Group Inc. (CSE: RYAH) since such tools help a lot to correlate and validate clinical study findings.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://cnw.fm/RYAH

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office

CNW420 is part of the InvestorBrandNetwork.